XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net Revenues:        
Revenues $ 191,214 $ 180,556 $ 545,444 $ 466,290
Cost of revenues 89,273 72,153 258,237 211,309
Gross profit 101,941 108,403 287,207 254,981
Operating expenses:        
Selling and Marketing Expense 8,995 6,407 27,378 20,234
General and administrative 14,821 12,654 43,782 38,418
Research and development 21,077 16,664 55,772 53,322
Total operating expenses 44,893 35,725 126,932 111,974
Income from operations 57,048 72,678 160,275 143,007
Non-operating income (expenses):        
Investment Income, Interest 2,427 1,202 8,320 3,156
Interest expense (6,698) (13,702) (23,918) (17,702)
Other Nonoperating Income (Expense) (5,094) 3,459 1,125 1,553
Total non-operating income (expenses), net (9,365) (9,041) (14,473) (12,993)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 47,683 63,637 145,802 130,014
Income tax provision 7,254 14,025 23,674 27,160
Income before equity in losses of unconsolidated affiliate 40,429 49,612 122,128 102,854
Equity in losses of unconsolidated affiliates   (390) (573) (1,476)
Net income attributable to Amphastar Pharmaceuticals, Inc.     121,555 101,378
Net income attributable to Amphastar Pharmaceuticals, Inc. $ 40,429 $ 49,222 $ 121,555 $ 101,378
Net income per share        
Earnings Per Share, Basic $ 0.83 $ 1.01 $ 2.50 $ 2.10
Earnings Per Share, Diluted $ 0.78 $ 0.91 $ 2.32 $ 1.91
Weighted-average shares used to compute net income per share:        
Weighted Average Number of Shares Outstanding, Basic 48,621 48,701 48,580 48,368
Diluted (in Shares) 51,862 53,921 52,307 52,997
Product [Member]        
Net Revenues:        
Revenues $ 188,819 $ 151,855 $ 525,836 $ 437,589
Product and Service, Other [Member]        
Net Revenues:        
Revenues $ 2,395 $ 28,701 $ 19,608 $ 28,701